{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T11:01:20Z","timestamp":1787655680777,"version":"build-2736575974"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,13]],"date-time":"2023-05-13T00:00:00Z","timestamp":1683936000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,13]],"date-time":"2023-05-13T00:00:00Z","timestamp":1683936000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Context<\/jats:title>\n                <jats:p>Cholangiocarcinoma (CCA), a malignancy of the biliary tract epithelium is of increasing importance due to its rising incidence worldwide. There is a lack of data on cirrhosis in intrahepatic CCA (iCCA) and how it affects overall survival and prognosis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Objectives<\/jats:title>\n                <jats:p>The primary objective of this study was to examine if there were differences in survival outcomes between iCCA patients with concomitant cirrhosis and those without cirrhosis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The National Cancer Database (NCDB) was used to identify and study patients with iCCA from 2004 to 2017. The presence of cirrhosis was defined using CS Site-Specific Factor 2 where 000 indicated no cirrhosis and 001 indicated the presence of cirrhosis. Descriptive statistics were utilized for patient demographics, disease staging, tumor, and treatment characteristics. Kaplan-Meier (KM) method with log-rank test and a multivariate logistic regression model was used to assess if the presence of cirrhosis in iCCA was associated with survival status and long-term survival (60 or more months after diagnosis).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>There were 33,160 patients with CCA in NCDB (2004\u20132017), of which 3644 patients were diagnosed with iCCA. One thousand fifty-two patients (28.9%) had cirrhosis as defined by Ishak Fibrosis score 5\u20136 on biopsy and 2592 patients (71.1%) did not meet the definition for cirrhosis. Although in univariate analyses using KM\/log-rank tests showed a survival advantage for non-cirrhotic patients, there was no statistically significant association found between cirrhosis and survival status (OR\u2009=\u20090.82, <jats:italic>p<\/jats:italic>\u2009=\u20090.405) or long-term survival (OR\u2009=\u20090.98, <jats:italic>p<\/jats:italic>\u2009=\u20090.933) when multivariate analysis was used. iCCA patients with cirrhosis and Stage 1 tumor had the highest median OS (132\u2009months) vs 73.7\u2009months in the non-cirrhotic arm, while patients with stage IV disease who had cirrhosis had half the survival time of those without. Our data thus indicates that the presence of cirrhosis is not an independent prognostic factor for survival.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12876-023-02710-w","type":"journal-article","created":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T12:57:37Z","timestamp":1684155457000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Cirrhosis in intrahepatic cholangiocarcinoma: prognostic importance and impact on survival"],"prefix":"10.1186","volume":"23","author":[{"given":"Nimish","family":"Thakral","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresita","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olger","family":"Nano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-Ha","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenae","family":"Samuels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atif","family":"Hussein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,13]]},"reference":[{"issue":"9935","key":"2710_CR1","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1016\/S0140-6736(13)61903-0","volume":"383","author":"N Razumilava","year":"2014","unstructured":"Razumilava N, Gores GJ. Cholangiocarcinoma. Lancet. 2014;383(9935):2168\u201379. https:\/\/doi.org\/10.1016\/S0140-6736(13)61903-0.","journal-title":"Lancet"},{"issue":"27","key":"2710_CR2","doi-asserted-by":"publisher","first-page":"3818","DOI":"10.1038\/sj.onc.1209558","volume":"25","author":"T Roskams","year":"2006","unstructured":"Roskams T. Liver stem cells and their implication in hepatocellular and cholangiocarcinoma. Oncogene. 2006;25(27):3818\u201322. https:\/\/doi.org\/10.1038\/sj.onc.1209558.","journal-title":"Oncogene."},{"issue":"23","key":"2710_CR3","doi-asserted-by":"publisher","first-page":"3140","DOI":"10.1200\/JCO.2011.35.6519","volume":"29","author":"MC de Jong","year":"2011","unstructured":"de Jong MC, Nathan H, Sotiropoulos GC, et al. Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment. J Clin Oncol. 2011;29(23):3140\u20135. https:\/\/doi.org\/10.1200\/JCO.2011.35.6519.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2710_CR4","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1002\/hep.22310","volume":"48","author":"B Blechacz","year":"2008","unstructured":"Blechacz B, Gores GJ. Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology. 2008;48(1):308\u201321. https:\/\/doi.org\/10.1002\/hep.22310.","journal-title":"Hepatology."},{"issue":"12","key":"2710_CR5","doi-asserted-by":"publisher","first-page":"419","DOI":"10.4254\/wjh.v2.i12.419","volume":"2","author":"Y Nakanuma","year":"2010","unstructured":"Nakanuma Y, Sato Y, Harada K, Sasaki M, Xu J, Ikeda H. Pathological classification of intrahepatic cholangiocarcinoma based on a new concept. World J Hepatol. 2010;2(12):419\u201327. https:\/\/doi.org\/10.4254\/wjh.v2.i12.419.","journal-title":"World J Hepatol"},{"issue":"Suppl 1","key":"2710_CR6","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/liv.14095","volume":"39","author":"SA Khan","year":"2019","unstructured":"Khan SA, Tavolari S, Brandi G. Cholangiocarcinoma: epidemiology and risk factors. Liver Int. 2019;39(Suppl 1):19\u201331. https:\/\/doi.org\/10.1111\/liv.14095.","journal-title":"Liver Int"},{"issue":"1","key":"2710_CR7","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1002\/hep.24351","volume":"54","author":"GL Tyson","year":"2011","unstructured":"Tyson GL, El-Serag HB. Risk factors for cholangiocarcinoma. Hepatology. 2011;54(1):173\u201384. https:\/\/doi.org\/10.1002\/hep.24351.","journal-title":"Hepatology."},{"key":"2710_CR8","unstructured":"Forty-Year Trends in Cholangiocarcinoma Incidence in the U.S.: Intrahepatic Disease on the Rise. Accessed 9 Oct 2021. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4861366\/"},{"issue":"18","key":"2710_CR9","doi-asserted-by":"publisher","first-page":"4148","DOI":"10.1002\/cncr.24472","volume":"115","author":"I Park","year":"2009","unstructured":"Park I, Lee JL, Ryu MH, et al. Prognostic factors and predictive model in patients with advanced biliary tract adenocarcinoma receiving first-line palliative chemotherapy. Cancer. 2009;115(18):4148\u201355. https:\/\/doi.org\/10.1002\/cncr.24472.","journal-title":"Cancer."},{"issue":"9","key":"2710_CR10","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1016\/j.ejca.2014.02.015","volume":"50","author":"MG McNamara","year":"2014","unstructured":"McNamara MG, Templeton AJ, Maganti M, et al. Neutrophil\/lymphocyte ratio as a prognostic factor in biliary tract cancer. Eur J Cancer. 2014;50(9):1581\u20139. https:\/\/doi.org\/10.1016\/j.ejca.2014.02.015.","journal-title":"Eur J Cancer"},{"issue":"6","key":"2710_CR11","doi-asserted-by":"publisher","first-page":"428","DOI":"10.3978\/j.issn.2078-6891.2014.081","volume":"5","author":"RD Peixoto","year":"2014","unstructured":"Peixoto RD, Renouf D, Lim H. A population based analysis of prognostic factors in advanced biliary tract cancer. J Gastrointest Oncol. 2014;5(6):428\u201332. https:\/\/doi.org\/10.3978\/j.issn.2078-6891.2014.081.","journal-title":"J Gastrointest Oncol"},{"key":"2710_CR12","unstructured":"Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4007244\/.\u00a0Accessed 9 Oct 2021."},{"key":"2710_CR13","doi-asserted-by":"crossref","unstructured":"Boffa DJ, Rosen JE, Mallin K, Loomis A, Gay G, Palis B, et al. Using the national cancer database for outcomes research a review. JAMA Oncol. 2017:3.","DOI":"10.1001\/jamaoncol.2016.6905"},{"issue":"5","key":"2710_CR14","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.amjsurg.2004.07.034","volume":"188","author":"N Farnsworth","year":"2004","unstructured":"Farnsworth N, Fagan SP, Berger DH, Awad SS. Child-Turcotte-Pugh versus MELD score as a predictor of outcome after elective and emergent surgery in cirrhotic patients. Am J Surg. 2004;188(5):580\u20133. https:\/\/doi.org\/10.1016\/j.amjsurg.2004.07.034.","journal-title":"Am J Surg"},{"key":"2710_CR15","unstructured":"EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis - Journal of Hepatology. https:\/\/www.journal-of-hepatology.eu\/article\/S0168-8278(18)31966-4\/fulltext. Accessed\u00a02018."},{"key":"2710_CR16","doi-asserted-by":"publisher","unstructured":"Martin P, DiMartini A, Feng S, Brown R Jr, Fallon M. Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Hepatol. 2014;59(3):1144-65. https:\/\/doi.org\/10.1002\/hep.26972.","DOI":"10.1002\/hep.26972"},{"issue":"2","key":"2710_CR17","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1002\/jhbp.159","volume":"22","author":"K Hashimoto","year":"2015","unstructured":"Hashimoto K, Miller CM. Liver transplantation for intrahepatic cholangiocarcinoma. J Hepato-Biliary-Pancreatic Sci. 2015;22(2):138\u201343. https:\/\/doi.org\/10.1002\/jhbp.159.","journal-title":"J Hepato-Biliary-Pancreatic Sci"},{"issue":"4","key":"2710_CR18","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1007\/s11605-011-1419-8","volume":"15","author":"YY Li","year":"2011","unstructured":"Li YY, Li H, Lv P, et al. Prognostic value of cirrhosis for intrahepatic cholangiocarcinoma after surgical treatment. J Gastrointest Surg. 2011;15(4):608\u201313. https:\/\/doi.org\/10.1007\/s11605-011-1419-8.","journal-title":"J Gastrointest Surg"},{"key":"2710_CR19","doi-asserted-by":"publisher","first-page":"6543423","DOI":"10.1155\/2017\/6543423","volume":"2017","author":"S Jeong","year":"2017","unstructured":"Jeong S, Gao L, Tong Y, et al. Prognostic impact of cirrhosis in patients with intrahepatic cholangiocarcinoma following hepatic resection. Can J Gastroenterol Hepatol. 2017;2017:6543423. https:\/\/doi.org\/10.1155\/2017\/6543423.","journal-title":"Can J Gastroenterol Hepatol"},{"issue":"47","key":"2710_CR20","doi-asserted-by":"publisher","first-page":"4438","DOI":"10.18632\/oncotarget.27820","volume":"11","author":"NA Levy","year":"2020","unstructured":"Levy NA, Kern G, Shepshelovich D, Shibolet O, Hershkoviz R, Isakov O. Effect of liver fibrosis on survival in patients with intrahepatic cholangiocarcinoma: a SEER population-based study. Oncotarget. 2020;11(47):4438\u201347. https:\/\/doi.org\/10.18632\/oncotarget.27820.","journal-title":"Oncotarget."},{"issue":"6","key":"2710_CR21","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1002\/lt.25737","volume":"26","author":"E De Martin","year":"2020","unstructured":"De Martin E, Rayar M, Golse N, et al. Analysis of liver resection versus liver transplantation on outcome of small intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma in the setting of cirrhosis. Liver Transpl. 2020;26(6):785\u201398. https:\/\/doi.org\/10.1002\/lt.25737.","journal-title":"Liver Transpl"},{"issue":"5","key":"2710_CR22","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1097\/MEG.0000000000001036","volume":"30","author":"D Jesper","year":"2018","unstructured":"Jesper D, Heyn SG, Schellhaas B, et al. Effects of liver cirrhosis and patient condition on clinical outcomes in intrahepatic cholangiocarcinoma: a retrospective analysis of 156 cases in a single center. Eur J Gastroenterol Hepatol. 2018;30(5):552\u20136. https:\/\/doi.org\/10.1097\/MEG.0000000000001036.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"6","key":"2710_CR23","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1159\/000509059","volume":"9","author":"F Tovoli","year":"2020","unstructured":"Tovoli F, Guerra P, Iavarone M, et al. Surveillance for hepatocellular carcinoma also improves survival of incidentally detected intrahepatic cholangiocarcinoma arisen in liver cirrhosis. Liver Cancer. 2020;9(6):744\u201355. https:\/\/doi.org\/10.1159\/000509059.","journal-title":"Liver Cancer"},{"key":"2710_CR24","doi-asserted-by":"crossref","unstructured":"Becerra AZ, Eure D, Fungwe C, Justiniano CF, Aquina CT. To risk adjust or not to risk adjust for sociodemographics\u2014that is the question, so what is the answer? J Hosp Manag Heal Policy. 2020:4.","DOI":"10.21037\/jhmhp.2020.03.01"},{"key":"2710_CR25","doi-asserted-by":"publisher","unstructured":"Welzel TM, McGlynn KA, Hsing AW, O'Brien TR, Pfeiffer RM. Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United States. J Natl Cancer Inst. 2006;98(12):873-5. https:\/\/doi.org\/10.1093\/jnci\/djj234.","DOI":"10.1093\/jnci\/djj234"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-023-02710-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-023-02710-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-023-02710-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T12:58:49Z","timestamp":1684155529000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-023-02710-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,13]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2710"],"URL":"https:\/\/doi.org\/10.1186\/s12876-023-02710-w","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,13]]},"assertion":[{"value":"7 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All experimental protocols were approved by the Institutional Review Board of Memorial Healthcare System. All methods were carried out in accordance with relevant guidelines and regulations. Data was obtained from the National Cancer Database, containing no identifiable patient information. The human data used in the study was anonymized.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"151"}}